Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2018 December;109(6) > Minerva Medica 2018 December;109(6):443-50



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Medica 2018 December;109(6):443-50

DOI: 10.23736/S0026-4806.18.05628-8


lingua: Inglese

Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease

Peter JIRAK 1, Moritz MIRNA 1, Bernhard WERNLY 1, Vera PAAR 1, Marcus THIEME 2, Stefan BETGE 2, Marcus FRANZ 2, Uta HOPPE 1, Alexander LAUTEN 3, 4, Jürgen KAMMLER 5, Paul C. SCHULZE 2, Michael LICHTENAUER 1 , Daniel KRETZSCHMAR 2

1 Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University, Salzburg, Austria; 2 Department of Cardiology, Clinic of Internal Medicine I, University Heart Center Thüringen, Friedrich Schiller University, Jena, Germany; 3 Department of Cardiology, Charité Medical University, Berlin, Germany; 4 German Center for Cardiovascular Research (DZHK), Berlin, Germany; 5 Department of Cardiology, Kepler University Hospital, Linz, Austria

BACKGROUND: Peripheral artery disease (PAD) is a common form of manifestation of atherosclerosis. PAD has a considerable impact on morbidity, hospitalization rates and health-care costs. Biomarkers have been introduced in many cardiovascular disease entities over the last years. However, an analysis on the correlation of biomarker levels and PAD is still lacking.
METHODS: A total of 106 patients were enrolled in this current study, 51 that were diagnosed with PAD and 55 with excluded coronary and peripheral artery disease as controls. During outpatient visits, plasma samples of all patients were obtained and analyzed for sST2 (hemodynamics and inflammation), galectin-3 (fibrosis and remodeling), GDF-15 (remodeling and inflammation), suPAR (inflammation), and fetuin-A (vascular calcification) by use of ELISA after informed consent.
RESULTS: Compared with controls, patients with PAD showed significantly higher levels of sST2 (5248 vs. 7503 pg/mL, P<0.001), suPAR (2267 vs. 2414 pg/mL, P=0.02), galectin-3 (2795 vs. 4494 pg/mL, P<0.001), and GDF-15 (549 vs. 767 pg/mL, P<0.001). Fetuin-A showed a trend towards lower levels in patients with PAD (117 vs. 100 ng/mL, P=0.119).
CONCLUSIONS: Circulating levels of sST2, suPAR, galectin-3, and GDF-15 were significantly elevated in PAD patients. In contrast, fetuin-A levels showed a decrease in PAD patients indicating increased vascular calcification. Thus, by incorporating different pathophysiological processes present in PAD, tested novel biomarkers facilitate a more precise diagnosis as well as a more accurate evaluation of disease severity and progression.

KEY WORDS: Peripheral arterial disease - Atherosclerosis - Inflammation - Biomarkers

inizio pagina